Daniele Rodolico

Resident physician @unipisa | MD @unicatt | Emerging Leader @worldheartfed | Previously @karolinskainst + @mghcvrc + @McGovernMed | Past fellow @ArmeniseHarvard

[Daniele Rodolico @DanieleRodolico]

❓How can studying #CardiacMetabolism help with the prevention, diagnosis and treatment of #HeartFailure?

📌We try to answer in our Review Topic of the Month @JACC #JACCHF
https://t.co/unQlQSDdQh

👥@HTaegtmeyer @gabrieleschiat1 @BiykemB @anita_deswal

#CardioTwitter #CardioEd

[Gianluigi Savarese @GianluSava]

Obesity- treatment target in patients with HFpEF. Read more on the interplay between obesity and HFpEF in our HFA scientific statement. #cardiotwitter @HFA_President

[Gabriele G. Schiattarella @gabrieleschiat1]

🚨 Out now in Circulation Research 🚨
So proud with @mkontari to launch this Compendium on Interorgan Crosstalk in Heart Failure & Cardiometabolic Disease. Heart failure it’s systemic. Multiorgan. Dynamic. @CircRes @dzhk_germany @dhzcharite @MDC_Berlin

[Gianluigi Savarese @GianluSava]

#obesity in pts with #heartfailure: a common challenge and a therapeutic target in HFpEF. Do not miss our #ESC_HFA Scientific Statement on the topic!
https://t.co/TfTr1YdXNC
@EJHFEiC @HFA_President @HanCardiomd @_antocannata @MarcoMetra @markcpetrie20 @escardio @ESC_Journals

[Circulation @CircAHA]

No longer a disease of failure; after 100 years of tireless breakthrough science, HF is about function. @NMHheartdoc https://t.co/WpdkJJLAdU

[Muthu Vaduganathan @mvaduganathan]

Modern RCTs of GDMT in #HFpEF have been well represented with older adults (median age >70y) who carry a high burden of #frailty (upper range of FI>0.50)

Reassuringly, evidence supports that frail older adults benefit similarly (or even to a greater degree!) from core #GDMT👇🏾

[Muthu Vaduganathan @mvaduganathan]

Should polypharmacy in older adults dissuade treatment optimization in heart failure? No.

Contrary to common clinical beliefs, randomized data of core #GDMT suggests efficacy is greater, not lesser, among those on a large # of background medicines.

👇🏾

[Prof Amitava Banerjee💙 @amibanerjee1]

Back from #WHFEL 2024 seminar; straight on call but energised! A special week: the 10th cohort;the first time we have combined with the Leadership& Advocacy programme; & the end of my 6-year stint leading the programme with the amazing @worldheartfed team. An absolute privilege🙏🏽

[JAMA @JAMA_current]

2024 Lasker-DeBakey Clinical Medical Research Award winner @lotte_bjerre describes her discovery of GLP-1 for the development of therapies to treat patients with obesity. https://t.co/pww0ujMZzt

#Lasker2024

[Muthu Vaduganathan @mvaduganathan]

🔥 A new therapeutic era in #HFpEF

#FINEARTSHF with definitive evidence supporting the role of the non-steroidal MRA finerenone at #ESCCongress

Now in @NEJM

https://t.co/iRGr1fQ2jM

[Gregg W. Stone MD @GreggWStone]

Our viewpoint now in EHJ: A new framework to overcome the limitations of the "unsatisfactory MACE endpoint". The composite outcome of survival and improved quality of life - what pts want - will be tested in the RECHARGE trial of PCI v CABG in 1200 women and minority group pts.

[JAMA @JAMA_current]

JAMA Senior Editor Derek Angus of @PittTweet joins JAMA Editor in Chief @KBibbinsDomingo to discuss "The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided."

Hosted on @amaedhub.

https://t.co/bCdGVS5OQb

[JAMA @JAMA_current]

Viewpoint: Ali Abbasi, Lesley Curtis, and @DrCaliff_FDA discuss how pragmatic clinical research can help in evaluation of new technologies, benefit research sites in underresourced settings, and better inform regulatory decisions and clinical practice.

https://t.co/rwZTGwpsHY

[Anil Makam @AnilMakam]

@EWidera This might make your head explode

90% of the US population is now labeled as having cardiovascular, kidney, and metabolic (CKM) syndrome stage 1 or higher in this @JAMA_current piece

I'm penning a letter to JAMA that says 100% have pre-death

you in?

https://t.co/vFYp5Y4LD9

[JAMA @JAMA_current]

JAMA Guide to Statistics and Methods article discusses accounting for competing risks in clinical research. #CausalInference #MedTwitter #MedStats

https://t.co/CQq29N3ZWX

[Husam Salah @HusamSalah]

1/3 Check out this editorial with @FudimMarat in EJHF on GDMT & polypharmacy in HFpEF (https://t.co/gJha3qds13)

Original paper: post hoc analysis of PARAGON-HF (https://t.co/XWHpEvoMMz)

@EJHFEiC @ESC_Journals

[Gregg Fonarow MD @gcfmd]

🚨Stunning!🚨

REVERSAL in the decline of heart failure ☠️ in the US 1999-2021

1999-2005 ⬇️ ☠️
2005-2012 ⬇️ ☠️
2012-2019 ⬆️ ☠️
2019-2021 ⬆️⬆️☠️

Age-adjusted HF related ☠️ rates higher in 2021 vs 1999!

WT😱🆘

https://t.co/a7au8TIdJ7

@JAMACardio @FudimMarat

[JACC Journals @JACCJournals]

SGLT2is increase risk of genital mycotic infection but not #UTI. Withdrawal of #SGLT2i led to adverse outcomes in #heartfailure. SGLT2i should be continued along with treatment for mild-moderate UTI/GMI. https://t.co/jeDCF4QeTz

(2/2) #JACC @vkittipibul @robmentz

[Giuseppe Biondi-Zoccai @gbiondizoccai]

Moving toward a comprehensive geriatric assessment and away from chronological age when envisioning TAVI in older adults: a must-read review in JACC: Advances https://t.co/Q8fY3LjVYs @JACCJournals

[Diego Segura-Rodríguez @SeguraCardio]

📌Physician perceptions, attitudes, & strategies towards implementing #GDMT💊 in #HeartFailure with reduced ejection fraction. A survey of the #HFA of the @escardio

#HFrEF #HF #CardioEd

[The Heart @ZHeart11768530]

🔴 Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure @JACCJournals

https://t.co/dVNfKg4PYw
#medical #MedEd #cardiology #CardioTwitter #CVD #CardioEd #medtwitter #CardioEd